Company Name Euthymics Bioscience
Mailing Address 35 Braintree Hill Office Park Braintree, MA 02184
Company Description Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment.
Proceeds Purposes The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV’s unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs.
Venture Investor Novartis Venture Fund
Venture Investor Venture Investors
Venture Investor Hambrecht & Quist Capital Management